PTO/SB/05 (01-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Under the Paperwork Reduction Act of 1995, no persons are required to	respond to a collection of inform	ation unless it displays a valid OMB control number.	
UTILITY PATENT APPLICATION TRANSMITTAL	Attomey Docket No.	9/279	
	First Inventor	Shirlynn CHEN	
	Title	Phamraceutical Compositions for Hepatitis C Viral Protease Inhibitors	
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Evoress Mail Lahel No	EV 315124305 US	

• ••	PPLICATION ELEMENTS ter 600 concerning utility patent application contents.	ADDRESS TO: Mall Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450					
2. Applicant cl See 37 CFF 3. Specificatio (preferred arr	on [Total Pages52] rrangement set forth below)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. Paper					
- Cross Refe - Statement I - Reference t or a comput - Background	e title of the invention erence to Related Applications : Regarding Fed sponsored R & D t to sequence listing, a table, uter program listing appendix ad of the Invention mary of the Invention						
- Brief Descri	ription of the Drawings (if filed)	c. Statements verifying identity of above copies					
- Detailed De		ACCOMPANYING APPLICATION PARTS					
- Claim(s)	f the Disclosure	ACCOMPANTING ALL EIGATION FAMILE					
	(35 U.S.C. 113) [Total Sheets]	9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of					
5. Oath or Declarati a. Newly e.	tion [Total Sheets] executed (original or copy)	(when there is an assignee) Attorney English Translation Document (if applicable) 12. Information Disclosure Copies of IDS					
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)		Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503)					
i. DEL	LETION OF INVENTOR(S)	(Should be specifically itemized) 15. Certified Copy of Priority Document(s)					
Signer	ed statement attached deleting inventor(s)	(if foreign priority is claimed)					
	e in the prior application, see 37 CFR	16. Nonpublication Request under 35 U.S.C. 122					
1,00,1	(d)(2) and 1.33(b).	(b)(2)(B)(i). Applicant must attach form PTO/SB/35					
6. Applicatio	on Data Sheet. See 37 CFR 1.76	or its equivalent.					
-		17. U Other:					
15 " CONTINUE	TO TO TO THE PROPERTY OF THE PARTY OF THE PA						
18. If a CONTINUIN specification following	NG APPLICATION, check appropriate box, and suping the title, or in an Application Data Sheet under 3	pply the requisite information below and in the first sentence of the 37 CFR 1.76:					
Continuation	on Divisional Continua	ation-in-part (CIP) of prior application No.:					
Prior application inform	nation: Examiner	Art Unit:					
For CONTINUATION C	OR DIVISIONAL APPS only: The entire disclosure of the	he prior application, from which an oath or declaration is supplied under Box					
5b is considered a pa	eart of the disclosure of the accompanying continuation only be relied upon when a portion has been inadven	n or divisional application and is hereby incorporated by reference.					
The incorporation can		IDENCE ADDRESS					
Customer N	Number: 28509	OR Correspondence address below					
Name							
Address							
City		State Zip Code					
Country	1	Telephone Fax					
Name (Print/Type)	Philip I. Datlow	Registration No. (Attorney/Agent) 41,482					
Signature	Philip I. Datiow	Date March 23, 2004					
0.5							

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

March 23, 2004

Date

Under the	Paperwo	rk Reduc	ction Act of 1995	o, no persons are requi	red to re	to respond to a collection of information unless it displays a valid OMB control number					
FEE TRANSMITTAL				Complete if Known							
PEE IRANSMITTAL		-	 Application Number 			Not Yet Assigned					
for FY 2004			Filing Date		March	March 23, 2004					
				First Named Inventor		Shirlyn	Shirlynn CHEN				
Effective 10/01/2003. Patent fees are subject to annual revision.				Examiner Name Not Yet Assigned		t Assigned					
Applicar	nt claims	small	entity status. S	See 37 CFR 1.27		- Art Unit Not Yet Assigned		t Assigned			
TOTAL AM	MOUNT	OF PA	YMENT	(\$) 950.00		Attorney Docket No. 9/279			<i>_</i>		
METH	OD OF	PAYN	IENT (check	all that apply)		FEE CALCULATION (continued)					
Check	Credi	t card	Money [Other None		3. ADDITIONAL FEES					
Deposit .	Account:		0.00.		l	Large Entity Small Entity					
Deposit			02 2055		Fee Code	Fee e (\$)	Fee Code	Fee (\$)	Fee I	Description	Fee Paid
Account Number	Account U2-2955			1051	130	2051	65 Sui	rcharge - late	filing fee or oath		
Deposit Account Boehringer Ingelheim Corporation			1052	50	2052		rcharge - late ver sheet	charge - late provisional filing fee or er sheet			
Name The Director I	e authori	zed to:	check all that a	20/v)	1053	130	1053	130 No.	n-English spe	ecification	
Charge fee				lit any overpayments	1812	2,520	1812 2	2,520 For	r filing a reque	est for ex parte reexamination	
= -	• •		or any underpay	ment of fee(s)	1804	920*	1804		questing pub aminer action	lication of SIR prior to	
Charge fee	(s) indica	ted belov	w, except for th	e filing fee	1805	1,840*	1805			lication of SIR after	
to the above-id					1251	110	2251		aminer action	ply within first month	
			LCULATION		1252		2252			ply within second month	
1. BASIC F					1253		2253			eply within third month	
	Fee Fe	<u> </u>	e Description	Fee Paid	1	1,480	2254			ply within fourth month	
	Code (\$)		t latita - Elimon foro		1255	2,010	2255			ply within fifth month	
1001 770 1002 340	2001 38 2002 17		Utility filing fee Design filing fee	770.00	1401		2401	165 No	otice of Appe	al .	
1002 540	2002 17		Plant filing fee		1402		2402			support of an appeal	
1003 330	2004 38		Reissue filing fe	<u> </u>	1403	290	2403		equest for ora		
1005 160			Provisional filing		1451	1,510	1451	1,510 Pe	tition to instit	ute a public use proceeding	
1000 100		-	BTOTAL (1)		1452	110	2452	55 Pe	tition to reviv	e - unavoidable	
				[\(\) \(\)	1453	1,330	2453	665 Pe	etition to reviv	e - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			1501	1,330	2501	665 Ut	ility issue fee	(or reissue)			
		, Е	xt <u>ra Claim</u> s	below Fee Paid	1502	480	2502	240 De	esign issue fe	е	
Total Claims Independent	30	-20**		18.00 = 180.00	1503	640	2503	320 PI	ant issue fee		
Claims		- 3** :		86.00 = 0	1460	130	1460	130 Pe	etitions to the	Commissioner	
Multiple Depe	nuent		L	290.00 =	1807	50	1807	50 Pr	rocessing fee	under 37 CFR 1.17(q)	
Large Entity Fee Fee		Entity Fee	Fee Descrip	tion	1806	180	1806			nformation Disclosure Stmt	
Code (\$)	Code				8021	40	8021	40 Re	ecording each	patent assignment per number of properties)	
1202 18	2202		Claims in exces		1809	770	2809	385 Fil	ling a submis	sion after final rejection	
1201 86 1203 290	2201 2203		•	aims in excess of 3 dent claim, if not paid	1810	770	2810		7 CFR 1.129 or each additio	a)) onal invention to be	
1204 86	2204		** Reissue inde	pendent claims				ex	amined (37 C	CFR 1.129(b))	
4005 40			over original	•	180°		2801 1802		•	ontinued Examination (RCE) spedited examination	\vdash
1205 18	2205	5 9	and over orig	ns in excess of 20 inal patent	1002	. 300	1 1002		a design app		
I SHRTOTAL (2) I(%) IOU.UUII						r fee (sp			D-14		<u></u>
**or number previously paid, if greater; For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)											
SUBMITTED BY (Complete (if applicable))											
Name (Print/Typ)е)	Philip	I. Datlow		T	Registra (Attomey/		41	1,482	Telephone 203-798-45	42

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

APPLICANT(S):

S. CHEN, et al.

SERIAL NO.:

Not Yet Assigned

CONFIRMATION NO.:

Not Yet Assigned

FILING DATE:

March 23, 2004

DOCKET NO.:

9/279

TITLE:

Pharmaceutical Compositions for Hepatitis C Viral Protease Inhibitors

- 1. Utility Patent Application Transmittal (1pg);
- 2. Fee Transmittal FY 2004 (1pg, in triplicate);
- 3. Express Mail Certificate (1pg);
- 4. Application Data Sheet (3pgs);
- 5. Specification (52pgs)
- 6. Drawings (2pgs)

Date Mailed: March 23, 2004

Express Mail Label No. EV 315124305 US

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT 06877-0368

Tel: (203) 798-4542 Date: March 23, 2004 "EXPRESS MAIL" LABEL NO.: EV 315124305 US

DEPOSIT DATE: March 23, 2004

I HEREBY CERTIFY THAT THE ABOVE PAPERS AND FEE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:

Commissioner for Patents Mail Stop Patent Application P. O. Box 1450 Alexandria, VA 22313-1450

Philip I Datlow Reg. No. 41,482